These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8432794

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 5. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I.
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL, García-Luna PP, Leal-Cerro A, Cortés A, Trujillo F, Villamil F, Vaquero F, Revuelta M, Astorga R.
    Med Clin (Barc); 1994 Jun 11; 103(2):59-64. PubMed ID: 8051973
    [Abstract] [Full Text] [Related]

  • 8. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
    Brue T, James-Deidier A, Louvet JP, Dewailly D, Roger P, Schlienger JL, Schaison G, Hartemann P, Jaquet P.
    Ann Endocrinol (Paris); 1991 Jun 11; 52(4):273-82. PubMed ID: 1818531
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP.
    J Endocrinol Invest; 1996 Jun 11; 19(7):472-9. PubMed ID: 8884542
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun 11; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Jun 11; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A.
    Fertil Steril; 1989 Dec 11; 52(6):930-5. PubMed ID: 2591571
    [Abstract] [Full Text] [Related]

  • 16. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov 11; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 17. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul 11; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 18. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G.
    Clin Endocrinol (Oxf); 1993 Feb 11; 38(2):165-76. PubMed ID: 8435897
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May 11; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

  • 20. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun 11; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.